Table 1.

Patient Characteristic.

Characteristic	Total (n = 69)	Group I (n = 42)	Group II (n = 27)	P value
Gender, Male	51 (73.9%)	29 (69.0%)	22 (81.5%)	.251
Age (lung cancer), yr-old	70.2 ± 11.2	68.5 ± 11.6	72.8 ± 10.2	.081
Smoke (pack per yr)	29.2 ± 32.5	26.0 ± 30.1	34.2 ± 36.1	.389
Lung cancer pathology				.094
Squamous cell carcinoma	19	9	11
Adenocarcinoma	41	31	13
Small cell carcinoma	5	2	3
Lung tumor dimension, cm	3.9 ± 2.2	3.5 ± 2.1	4.7 ± 2.2	.025∗
Dimension range, cm	0.8–10.2	0.8–9.0	1.3–10.2
Lung cancer stage				.023∗
I	16 (23.2%)	15 (35.7%)	1 (3.7%)
II	4 (5.8%)	2 (4.8%)	2 (7.4%)
III	15 (21.7%)	9 (21.4%)	6 (22.2%)
IV	31 (44.9%)	15 (35.7%)	16 (59.2%)
Unknown	3 (4.3%)	1 (2.4%)	2 (7.4%)
Primary hepato-GI cancer stage				.019∗
I + II	25 (4.3%)	15 (35.7%)	10 (37.0%)
III + IV	27 (4.3%)	21 (50%)	6 (22.2%)
Unknown	17 (4.3%)	6 (14.2%)	11 (40.7%)
Primary hepato-GI tumor treatment				.575
Surgery	55	33	22
TACE/RFA	10	6	4
Chemotherapy	14	11	3
Others	3	2	2
Secondary lung cancer treatment				.009∗
Surgery	24	19	5
Chemotherapy	22	14	8
Radiation therapy	10	7	3
Target therapy	11	7	4
Best supportive	9	1	8
Chest image follow up in OPD	38 (55.1%)	28 (66.7%)	10 (37.0%)	.025∗
Interval between primary and secondary tumors (mo)	51.2 ± 36.3	54.4 ± 30.3	46.2 ± 29.1	.535

GI = gastrointestinal, OPD = outpatient department, RFA = radiofrequency ablation, TACE = trans-arterial cutaneous embolization.

^∗P value less than .05;